FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.
Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.
NCI Names 15 to Director’s Consumer Liaison Group.
SAIC-Frederick Makes Awards To Proteomics Research Teams.
Latest State Cancer Statistics Released.
Smokers May Get Cessation Help From Medicare.
Funding Opportunities Listed.
Trending Stories
- Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Letai: MCEDs are a “great ideal”—alas, the data don’t support widespread use
“Projecting sub-ideal tests across a large population can cause harm,” Letai says, as Galleri cruises toward FDA approval - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- Cancer vaccine policy in limbo as CDC keeps canceling advisory meetings
